(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, UTRECHT, Netherlands & BOSTON, Mass. US, 02 December 2022) Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune and infectious diseases, and Gadeta B.V., an innovative clinical-stage biopharmaceutical company pioneering the development of gamma delta (??) TCR-based immunotherapies for solid tumors, announced today that they will collaborate on the first ?? ImmTAC® for solid tumors, including colorectal cancer.
UTRECHT, Netherlands and BOSTON, Oct. 20, 2022 /PRNewswire/ -- Gadeta B.V. ('Gadeta'), an innovative clinical-stage biopharmaceutical company pioneering the development of gamma delta (??) T-cell receptor (TCR)-based immunotherapies for solid tumors, today announced the formation of a Scientific Advisory Board comprised of internationally renowned leaders in oncology, T cell biology and strategic drug development. The Scientific Advisory Board will be chaired by Dr. Hagop Youssoufian and includes Dr. Guillem Argilés of Memorial Sloan Kettering Cancer Center, Dr Robbie Majzner of Stanford University School of Medicine, Professor Jamie Rossjohn of Monash University and Dr Cassian Yee of The University Texas MD Anderson Cancer Center.
UTRECHT, Netherlands and BOSTON, March 28, 2022 /PRNewswire/ -- Gadeta B.V. ('Gadeta'), a clinical-stage company developing innovative, gamma delta (??) T-cell receptor (TCR)-based immunotherapies for every cancer patient, is pleased to announce that Chief Executive Officer Marcel Zwaal and Chief Scientific Officer Mark Throsby will be presenting data on ?? TCR-based immunotherapies for solid tumors at the following upcoming scientific conferences.